![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/08\/1786387393_495_logo.jpg\"){kind=logo}
\u00a0<\/p>\n\u00a0<\/p>\n
UNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
FORM 6-K<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER<\/p>\n
\u00a0<\/p>\n
Pursuant to Rule 13a-16 or 15d-16<\/p>\n
of the Securities Exchange Act of 1934<\/p>\n
\u00a0<\/p>\n
August 6, 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0(Exact name
\nof Registrant as specified in its charter)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo All\u00e9 1<\/p>\n
DK- 2880, Bagsvaerd<\/p>\n
Denmark<\/p>\n
(Address of principal executive offices)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether the registrant files or will file annual reports under
\ncover of Form 20-F or Form 40-F<\/p>\n
\u00a0<\/p>\n
Form 20-F \u2612\u00a0\u00a0\u00a0\u00a0\u00a0
\n \u00a0\u00a0\u00a0\u00a0\u00a0Form 40-F \u2610<\/p>\n
\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/08\/1786387394_415_ca.jpg\")
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Trading in Novo Nordisk shares by board members, executives and associated persons<\/p>\n
\u00a0<\/p>\n
Bagsv\u00e6rd, Denmark, 6 August 2026 \u2014
\nThis company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company\u2019s board members,
\nexecutives and their associated persons in accordance with Article 19 of Regulation No. 596\/2014 on market abuse. The company\u2019s
\nboard members, executives and their associated persons have reported the transactions to Novo Nordisk.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
D\u00c9SIR\u00c8E JANTZEN ASGREEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status
\n Member of the Board of Directors<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
ELISABETH DAHL CHRISTENSEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status
\n Member of the Board of Directors<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
METTE B\u00d8JER JENSEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status
\n Member of the Board of Directors<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
SEMSI KILIC MADSEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status
\n Member of the Board of Directors<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
EMIL KONGSH\u00d8J LARSEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, International
\nOperations<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance with Restricted Shares programme
\n\u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
KARSTEN MUNK KNUDSEN<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, Chief Financial
\nOfficer (CFO)<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
KASPER B\u00d8DKER MEJLVANG<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, Global Manufacturing
\n& Supply<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
MAZIAR MIKE DOUSTDAR<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status
\n President and CEO<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance with Restricted Shares programme
\n\u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
MARTIN HOLST LANGE<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, R&D and Chief
\nScientific Officer (CSO)<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
THILDE GYNTHE B\u00d8GEBJERG KR\u00d8YER<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, Enterprise IT &
\nQuality<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
1
\n Details of the person discharging managerial responsibilities\/person closely associated<\/p>\n
a)<\/p>\n
Name of the Board<\/p>\n
member\/Executive\/Associated Person<\/p>\n
TANIA SABROE<\/p>\n
2
\n Reason for the notification<\/p>\n
a)
\n Position\/status<\/p>\n
Executive Vice President, People,
\nOrganisation & Corporate Affairs<\/p>\n
b)
\n Initial notification\/Amendment
\n Initial notification<\/p>\n
3
\n Details of the issuer<\/p>\n
a)
\n Name
\n Novo Nordisk A\/S<\/p>\n
b)
\n LEI
\n 549300DAQ1CVT6CXN342<\/p>\n
4
\n Details of the transaction(s)<\/p>\n
a)<\/p>\n
Description of the financial instrument,
\ntype of instrument,<\/p>\n
Shares
\n \u00a0
\n \u00a0<\/p>\n
Identification code
\n Novo Nordisk B DK0062498333
\n \u00a0<\/p>\n
b)
\n Nature of the transaction<\/p>\n
Other transaction (vesting of shares in accordance
\nwith Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares)<\/p>\n
c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0<\/p>\n
DKK 294.30
\n 74<\/p>\n
\u00a0<\/p>\n
d)<\/p>\n
Aggregated information<\/p>\n
\u00b7\u00a0 Aggregated volume<\/p>\n
\u00b7\u00a0 Price<\/p>\n
74 shares<\/p>\n
DKK 21,778.20<\/p>\n
e)
\n Date of the transaction
\n 2026-08-05<\/p>\n
f)
\n Place of the transaction
\n Outside a trading venue<\/p>\n
\u00a0<\/p>\n
Novo Nordisk is a leading global healthcare
\ncompany founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our
\nheritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately
\ncure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s
\nB shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
\nnovonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Contacts for further information<\/p>\n
\u00a0<\/p>\n
Media:
\n \u00a0<\/p>\n
Ambre James-Brown<\/p>\n
+45 3079 9289<\/p>\n
abmo@novonordisk.com<\/p>\n
Liz Skrbkova
\n (US)<\/p>\n
+1 609 917 0632<\/p>\n
lzsk@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Investors:
\n \u00a0<\/p>\n
Michael Novod<\/p>\n
+45 3075 6050<\/p>\n
nvno@novonordisk.com<\/p>\n
Sina Meyer<\/p>\n
+45 3079 6656<\/p>\n
azey@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Alex Bruce<\/p>\n
+45 3444 2613<\/p>\n
axeu@novonordisk.com<\/p>\n
Mads Berner Bruun<\/p>\n
+45 3075 2936<\/p>\n
mbbz@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Christoffer Togo Solgaard-Tullin<\/p>\n
+45 3079 1471<\/p>\n
cftu@novonordisk.com<\/p>\n
Ida Schaap Melvold<\/p>\n
+45 3077 5649<\/p>\n
idmg@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Frederik Taylor Pitter (US)<\/p>\n
+1 609 613 0568<\/p>\n
fptr@novonordisk.com<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo Nordisk A\/S<\/p>\n
Investor Relations<\/p>\n
Novo Alle 1<\/p>\n
2880 Bagsv\u00e6rd<\/p>\n
Denmark<\/p>\n
Telephone:<\/p>\n
+45 4444 8888<\/p>\n
\nwww.novonordisk.com
CVR no: 24 25 67 90<\/p>\n
\u00a0\u00a0\u00a0Company
\n announcement No 49 \/ 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
\nduly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
Date: August 6, 2026<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0<\/p>\n
Maziar Mike Doustdar<\/p>\n
Chief Executive Officer<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 \u00a0 FORM 6-K \u00a0 \u00a0 REPORT OF…\n","protected":false},"author":2,"featured_media":143334,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[68562,68565,68564,68563,68566,43471,272,3859,67731],"class_list":["post-143333","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-100th-anniversary-shares","tag-778-20","tag-dkk-21","tag-dkk-294-30","tag-global-healthcare","tag-insider-transactions","tag-novo-nordisk","tag-nvo","tag-restricted-shares"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117072691948397727","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/143333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=143333"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/143333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/143334"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=143333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=143333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=143333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}